Posts Tagged Health
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
Posted by admin in Chairman, Chief executive officer, Emergent BioSolutions, Infectious disease, Profile, U.S. Food and Drug Administration, Vice President, fuad, fuad el-hibri on August 13th, 2009
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product BioThrax? (Anthrax Vaccine Adsorbed) is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent BioSolutions Inc. has a market cap of $511.8 million; its shares were traded at around $16.91 with a P/E ratio of 13.1 and P/S ratio of 2.8.
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=f7955583-8ff2-4f2e-b016-6d930ead00f7)
Emergent BioSolutions buys flu vaccine maker
Posted by admin in Uncategorized on July 14th, 2009
Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent’s strategy to expand its product portfolio with a drug candidate focused on infectious disease. Currently, most of Emergent’s business comes from government contracts for biodefense. Emergent will acquire PSC’s ongoing operations, including FluBlok, a Phase III recombinant influenza vaccine candidate, and certain other assets. “The acquisition of FluBlok is consistent with Emergent’s strategy of expanding its product portfolio with a vaccine candidate focused on a major infectious disease,” said Fuad El-Hibri, Emergent’s CEO. The company recently bought rival VaxGen’s anthrax vaccine business.
![Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=da85c4b0-268a-48b5-8cd6-f2a480bb3bc2)